The Wolverine Stack: BPC-157 With TB-500

Where does the name come from?

The Wolverine stack is a nickname, used in online marketing and forums, for taking BPC-157 and TB-500 together; it borrows the name of a comic-book character known for healing quickly. It is not a drug, a formulation or a regimen defined by any regulator or journal. The phrase appears in no PubMed record ^[1], and no registered study combines the two peptides ^[4].

The pairing rests on the idea that the two work through different repair pathways and so add to each other. That idea comes from studying each peptide separately, mostly in animals and cells ^[19]. The same two peptides also appear, with GHK-Cu and sometimes KPV, in the injectable blends sold as GLOW and KLOW, covered in the review of GLOW and KLOW blends.

How do BPC-157 and TB-500 compare?

They are unrelated molecules with similar records. BPC-157 is a 15-amino-acid fragment of a protein first described in human gastric juice ^[19]. TB-500 is a synthetic fragment of thymosin beta-4, and analysis of products sold under the name identified it as a seven-residue piece of that 43-residue protein ^[7]. Neither has a published controlled trial, and both hold the same US and sporting position.

What has been tested together?

Almost nothing. Thirteen PubMed records name both peptides. Ten are review or overview articles, one is a laboratory method for detecting doping agents in blood, one is a rat study and one is a human chart review; none is indexed as a clinical trial ^[1]. ClinicalTrials.gov lists no study of the two together ^[4].

The human data on the combination come to four people. In a 2021 retrospective review of knee injections at one Florida practice, 4 of 16 patients received BPC-157 together with thymosin beta-4, which the paper calls TB4 without saying whether it was the full protein or the TB-500 fragment; 3 of the 4 reported significant relief in a telephone survey ^[2]. There was no comparison group, and the survey reached patients up to a year after treatment.

The one controlled test of the pair was in rats, and it did not find that the pair beat either peptide alone. In a 2026 study of 32 rats with a repaired Achilles tendon, split into four groups of eight, TB-500 alone produced the clearest gains in tendon strength and structure, BPC-157 alone improved tissue scores without reaching significance, and the combination "did not confer additional benefits compared to either agent alone" ^[3]. The authors called the study exploratory, and eight rats a group is a small test, but it is the only direct evidence on whether stacking adds anything.

What are the side effects of the stack?

They are not known for the pair, and barely known for either half. The BPC-157 reports that recorded safety, 14 people across two small pilots, found no adverse events ^{[10, 11]}; for TB-500, FDA states it has identified no human exposure data at all ^[13]. The BPC-157 safety record sets out what is and is not known about that half in full.

Taking two unstudied peptides at once adds a problem of its own: if something goes wrong, there is no way to tell which peptide caused it, or whether the combination did. Contents are a further unknown, since a laboratory analysis of products sold as TB-500 found that they did not consistently match their labels ^[18].

What did FDA say about each peptide?

FDA placed BPC-157 in Category 2 of its interim bulks list in September 2023 ^[17]. Its safety-risk page, current as of April 22, 2026, states that compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization," and that the agency lacks sufficient information to know whether it would cause harm in people ^[12].

For TB-500 the same page states that compounded drugs containing the fragment "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities," and that FDA "has not identified any human exposure data" on products containing it ^[13]. Both peptides left Category 2 in April 2026 without being added to Category 1, which ended the explicit bar without granting permission; the Category 2 removal page explains the difference.

Are BPC-157 and TB-500 allowed in sport?

No. Both are named on the World Anti-Doping Agency's 2026 Prohibited List, in force from January 1, 2026, and both are prohibited at all times, in and out of competition ^[14]. BPC-157 is named in section S0, non-approved substances, which covers any pharmacological substance not addressed elsewhere on the List that has no current approval by any government health authority for human therapeutic use: "This class covers many different substances including but not limited to BPC-157" ^[14]. TB-500 is named in section S2.3, growth factors and growth factor modulators: "Thymosin-β4 and its derivatives e.g. TB-500" ^[14].

An FDA compounding listing would change neither entry. TB-500's place in S2.3 does not depend on approval at all, and a compounding listing is not an approval of a drug for human therapeutic use, which is the test S0 applies ^[14]. The WADA status table sets out every molecule in the index against the List.

What would change if FDA acts on the advisory vote?

In July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding both peptides to the section 503A bulks list, each by a margin reported as 8 to 6 with one abstention in two independent law-firm accounts; FDA scientists had recommended against inclusion in each case ^{[15, 16]}. The vote is advisory, and FDA has issued no final rule for either.

If FDA does list them, licensed 503A pharmacies could compound each peptide for an individual patient's prescription, under the same framework that governs other bulk substances ^[17]. Listing would not make either an approved drug, would not create trial evidence for either, and would not test the combination. Each molecule is decided on its own, so the two could also end up in different places. The pending status page and the July 2026 vote ledger will carry the outcome when it issues.

Elsewhere in this index